Saturday 17 October 2026
Export NEO’s income statement to Excel — free account
NeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 11.2%, EPS grew 105.7%, free cash flow fell 16.2% and total debt rose 10.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
16.65
0.60
−3.48%
Follow NEO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 417.86 | 1,794.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 7 | 6 | 7 | 3 | 1 | 2 | 4 | 6 | 4 |
P/S ratio |
2.89 | 2.88 | 3.90 | 7.19 | 13.15 | 8.45 | 2.22 | 3.38 | 3.16 | 2.07 |
Altman Z-Score |
2.94 | 3.11 | 4.17 | 9.72 | 12.78 | 3.64 | 1.15 | 1.94 | 1.86 | 1.79 |
P/FCF ratio |
48.00 | 159.33 | 35.43 | 879.86 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
1.32 | 1.49 | 2.39 | 4.80 | 4.85 | 3.16 | 2.45 | 2.38 | 1.44 | 1.46 |
Beneish M-Score |
(2.33) | (2.64) | (2.56) | (2.37) | (2.33) | (2.42) | (2.65) | (2.69) | (2.64) | (2.68) |
P/Operating CF |
(2,776.71) | 120.26 | 69.87 | 874.89 | 976.76 | (206.97) | (306.41) | 112.56 | 212.99 | 1,121.72 |
P/B ratio |
4.09 | 4.03 | 3.37 | 5.79 | 8.42 | 3.69 | 1.13 | 2.13 | 2.31 | 1.80 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 16.13 | 16.12 | 29.48 | 16.85 | 43.86 | 52.32 | 58.64 |
EV/Sales |
3.27 | 3.25 | 4.25 | 7.01 | 12.89 | 8.50 | 2.42 | 3.60 | 3.39 | 2.60 |
EV/EBITDA |
26.26 | 30.08 | 36.39 | 65.63 | 218.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
35.29 | 43.24 | 26.25 | 122.63 | 3,922.41 | (154.11) | (18.69) | (1,091.01) | 319.18 | 361.35 |
EV/FCF |
54.37 | 179.44 | 38.58 | 858.01 | (207.22) | (45.32) | (14.55) | (69.39) | (65.86) | (95.87) |
Quick Ratio |
1.79 | 2.01 | 1.42 | 4.18 | 5.51 | 7.19 | 6.20 | 5.67 | 1.78 | 3.61 |
Current Ratio |
2.07 | 2.35 | 1.70 | 4.55 | 6.13 | 7.81 | 6.73 | 6.20 | 1.98 | 4.26 |
Net Debt/EBITDA |
3.08 | 3.37 | 2.98 | (1.67) | (4.54) | (0.40) | (1.22) | (3.81) | (9.27) | (3.96) |
Debt/Assets |
30.04% | 29.10% | 20.99% | 14.10% | 17.92% | 28.91% | 31.17% | 32.01% | 33.03% | 25.14% |
Debt/Equity |
0.62 | 0.58 | 0.33 | 0.20 | 0.26 | 0.49 | 0.54 | 0.57 | 0.60 | 0.41 |
Asset Turnover |
0.67 | 0.71 | 0.65 | 0.67 | 0.52 | 0.34 | 0.28 | 0.35 | 0.40 | 0.49 |
Operating CF/Net income |
(0.70) | (1.65) | 7.36 | 2.92 | 0.35 | 3.20 | 0.46 | 0.02 | (0.09) | (0.05) |
Capex/Depreciation |
(0.28) | (0.59) | (0.64) | (0.65) | (0.72) | (1.14) | (0.26) | (0.38) | (0.54) | (0.36) |
Interest Coverage |
0.22 | 0.52 | 1.61 | 3.50 | (1.99) | (14.45) | (20.79) | (15.60) | (13.92) | (30.88) |
| (16.51%) | (6.52%) | 2.47% | 1.93% | 0.69% | (0.93%) | (13.70%) | (9.07%) | (8.54%) | (12.42%) | |
| (8.95%) | (3.21%) | 1.43% | 1.32% | 0.49% | (0.58%) | (7.99%) | (5.14%) | (4.74%) | (7.21%) | |
ROIC |
0.53% | 0.70% | 1.51% | 1.87% | (1.52%) | (6.55%) | (8.94%) | (6.33%) | (5.45%) | (7.11%) |
Return on Tangible Assets |
(41.23%) | (12.74%) | 5.87% | 2.75% | 0.90% | (1.19%) | (23.35%) | (14.85%) | (20.24%) | (28.98%) |
Average Days of Receivables |
87.41 | 91.80 | 101.45 | 84.14 | 87.74 | 84.50 | 85.72 | 80.96 | 83.18 | 79.91 |
Research and Development Expense of Revenue |
2.01% | 1.51% | 1.08% | 2.08% | 1.85% | 4.52% | 5.95% | 4.62% | 4.72% | 5.10% |
Selling, General and Administrative Expense of Revenue |
37.89% | 39.28% | 41.27% | 42.89% | 43.12% | 58.63% | 60.95% | 53.06% | 52.14% | 50.23% |
Intangible Assets out of Total Assets |
0.66 | 0.64 | 0.67 | 0.46 | 0.34 | 0.52 | 0.54 | 0.53 | 0.53 | 0.60 |
Share Based Compensation of Revenue |
2.35% | 2.68% | 2.51% | 2.45% | 2.30% | 4.64% | 4.84% | 4.16% | 5.06% | 5.68% |
Graham Net Nets |
(0.14) | (0.13) | (0.07) | 0.03 | 0.03 | (0.02) | (0.12) | (0.07) | (0.07) | (0.10) |
Graham Number |
0.00 | 0.00 | 0.00 | 2.82 | 2.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(4.52%) | (1.61%) | (0.08%) | 0.24% | 0.06% | (0.18%) | (12.76%) | (4.39%) | (3.76%) | (7.14%) |
Free Cash Flow Yield |
2.08% | 0.63% | 2.82% | 0.11% | (0.47%) | (2.22%) | (7.51%) | (1.53%) | (1.63%) | (1.31%) |
Revenue per Share |
2.99 | 3.02 | 3.23 | 4.07 | 4.09 | 4.04 | 4.10 | 4.71 | 5.22 | 5.68 |
Operating CF per Share |
0.28 | 0.23 | 0.52 | 0.23 | 0.01 | (0.22) | (0.53) | (0.02) | 0.06 | 0.04 |
Capex per Share |
(0.10) | (0.17) | (0.17) | (0.20) | (0.27) | (0.53) | (0.15) | (0.23) | (0.32) | (0.19) |
Free Cash Flow per Share |
0.18 | 0.05 | 0.36 | 0.03 | (0.25) | (0.76) | (0.68) | (0.24) | (0.27) | (0.15) |
Cash per Share |
0.16 | 0.16 | 0.11 | 1.72 | 2.73 | 4.30 | 3.53 | 3.31 | 3.05 | 1.25 |
Shareholders Equity per Share |
2.11 | 2.17 | 3.74 | 5.05 | 6.39 | 9.24 | 8.03 | 7.50 | 7.12 | 6.53 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.11 | 2.17 | 3.74 | 5.05 | 6.39 | 9.24 | 8.03 | 7.50 | 7.12 | 6.53 |
Free Cash Flow |
13.94 | 4.35 | 30.48 | 3.34 | (27.64) | (90.86) | (84.79) | (30.70) | (34.04) | (19.71) |
Working Capital |
40.71 | 49.40 | 42.74 | 226.83 | 375.55 | 594.28 | 515.36 | 500.51 | 294.78 | 287.99 |
Capital Expenditures |
(7.54) | (13.69) | (14.31) | (20.03) | (29.10) | (64.14) | (18.79) | (28.75) | (41.06) | (24.94) |
Net Current Asset Value |
(94.57) | (86.62) | (80.90) | 88.64 | 154.69 | (79.99) | (136.72) | (142.88) | (139.68) | (146.98) |
EV/EBIT |
351.71 | 268.78 | 117.12 | 220.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.06 | 0.05 | 0.05 | 0.07 | 0.13 | 0.04 | 0.05 | 0.06 | 0.03 |
Price to Operating Income |
310.53 | 238.66 | 107.53 | 225.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.78 | 0.63 | 0.37 | 0.48 | 0.47 | 0.51 | 0.71 | 0.82 | 0.80 | 0.82 |
Cash ROIC |
5.02% | 1.53% | 6.99% | 0.43% | (2.37%) | (4.20%) | (4.29%) | (1.62%) | (1.86%) | (1.47%) |
Accounts Receivable Turnover |
4.44 | 4.14 | 4.03 | 4.78 | 4.42 | 4.42 | 4.40 | 4.72 | 4.69 | 4.70 |
Accounts Payable Turnover |
9.14 | 10.16 | 10.59 | 11.35 | 11.61 | 13.86 | 16.75 | 16.99 | 17.67 | 18.48 |
Inventory Turnover |
23.54 | 20.15 | 18.54 | 18.39 | 11.77 | 11.23 | 13.50 | 14.33 | 14.56 | 14.93 |
Average Days of Payables |
45.81 | 27.58 | 43.41 | 33.69 | 35.24 | 22.00 | 23.26 | 21.39 | 21.29 | 20.40 |
Days of Inventory on Hand |
17.07 | 19.73 | 21.12 | 24.80 | 41.68 | 28.73 | 27.53 | 25.41 | 26.35 | 25.24 |
Average Receivables |
52.23 | 57.97 | 68.67 | 85.58 | 100.54 | 109.49 | 115.92 | 125.47 | 140.88 | 154.89 |
Average Payables |
14.62 | 13.62 | 14.11 | 18.67 | 22.27 | 21.44 | 19.22 | 20.42 | 20.97 | 22.35 |
Average Inventory |
5.68 | 6.86 | 8.06 | 11.53 | 21.97 | 26.46 | 23.84 | 24.22 | 25.45 | 27.66 |
Average Assets |
344.20 | 340.79 | 424.73 | 607.26 | 848.92 | 1,429.05 | 1,804.91 | 1,710.63 | 1,659.63 | 1,498.93 |
Average Common Equity |
186.62 | 167.84 | 246.20 | 413.93 | 600.85 | 901.29 | 1,053.15 | 969.78 | 921.94 | 869.45 |
Columns are period end dates